A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

The NHS has teamed up with the Dianne Oxberry Trust and Target Ovarian Cancer to bring a new awareness roadshow to the streets of Greater Manchester – including Wigan and Leigh – this March for ...

A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Researchers at the University of Pittsburgh have found special high-risk cells in the fallopian tubes that may trigger ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Researchers at the University of Pittsburgh have identified a novel trigger for a deadly form of ovarian cancer: a subset of ...

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.